A fatal hypotension by sildenafil in an end-stage renal disease patient with hypertension and abnormal pharmacokinetics of the medicine

Nephrology

Volumn 14, Issue 3, 2009, Pages 357-358

  Wada, Yoshihiro ^a   Kikuchi, Ken ^a   Imamura, Takahisa ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

SILDENAFIL;

AGED; ANAMNESIS; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; PRIORITY JOURNAL;

AGED; FATAL OUTCOME; HUMANS; HYPOTENSION; KIDNEY FAILURE, CHRONIC; MALE; PIPERAZINES; PURINES; PYRIMIDINONES; SULFONES; VASODILATOR AGENTS;

EID: 65349130634     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01132.x     Document Type: Article

References (5)

1. Data on File. At Pfizer, New York, NY, February 2002.
2. Muirhead GJ, Wilner K, Colburn W et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br. J. Clin. Pharmacol. 2002 53 : 21S 30S.
3. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J. Cardiol. 1999 83 : 35C 44C.
4. Attinà TM, Malatino LS, Maxwell SR et al. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J. Hypertens. 2008 26 : 501 7.
5. Milligan PA, Marshall SF, Karlsson MO. A population pharmacokinteic analysis of sildenafil citrate in patients with erectile dysfunction. Br. J. Clin. Pharmacol. 2002 53 : 45S 52S.